BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 36158267)

  • 1. Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy.
    Zhang CY; Liu S; Yang M
    World J Gastroenterol; 2022 Jul; 28(27):3346-3358. PubMed ID: 36158267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased prevalence but decreased survival of nonviral hepatocellular carcinoma compared to viral hepatocellular carcinoma in recent ten years.
    Chen TC; Hsiao SW; Chen YY; Yen HH; Su WW; Hsu YC; Huang SP; Su PY
    Sci Rep; 2024 Apr; 14(1):9068. PubMed ID: 38643245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.
    Chrysavgis L; Giannakodimos I; Diamantopoulou P; Cholongitas E
    World J Gastroenterol; 2022 Jan; 28(3):310-331. PubMed ID: 35110952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
    Bertot LC; Adams LA
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
    Meringer H; Shibolet O; Deutsch L
    World J Gastroenterol; 2019 Aug; 25(29):3929-3940. PubMed ID: 31413528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.
    Pais R; Fartoux L; Goumard C; Scatton O; Wendum D; Rosmorduc O; Ratziu V
    Aliment Pharmacol Ther; 2017 Nov; 46(9):856-863. PubMed ID: 28857208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.
    Chen J; Song S; Li X; Bian D; Wu X
    Saudi J Gastroenterol; 2022; 28(2):92-100. PubMed ID: 34810377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
    Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
    Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and prognosis of hepatocellular carcinoma in patients with diabetes.
    Nakatsuka T; Tateishi R
    Clin Mol Hepatol; 2023 Jan; 29(1):51-64. PubMed ID: 35903020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.
    Reeves HL; Zaki MY; Day CP
    Dig Dis Sci; 2016 May; 61(5):1234-45. PubMed ID: 26921078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High serum magnesium is associated with lower risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease.
    Yu YC; Paragomi P; Wang R; Liang F; Luu HN; Behari J; Yuan JM
    Cancer; 2023 Aug; 129(15):2341-2347. PubMed ID: 37052455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease.
    Than NN; Ghazanfar A; Hodson J; Tehami N; Coldham C; Mergental H; Manas D; Shah T; Newsome PN; Reeves H; Shetty S
    QJM; 2017 Feb; 110(2):73-81. PubMed ID: 27634970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease.
    Powell EE; Wong VW; Rinella M
    Lancet; 2021 Jun; 397(10290):2212-2224. PubMed ID: 33894145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma and non-alcoholic fatty liver disease.
    Golabi P; Rhea L; Henry L; Younossi ZM
    Hepatol Int; 2019 Nov; 13(6):688-694. PubMed ID: 31701393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research advances in the pathogenesis of non-alcoholic fatty liver disease-associated liver cancer].
    Huang W; Zhang XX
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):157-160. PubMed ID: 28297806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease.
    Tovoli F; Ferri S; Piscaglia F
    Curr Pharm Des; 2020; 26(32):3909-3914. PubMed ID: 32348210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
    Wang K; Wei Y; Xu R; Li Y; Mao C
    Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.